(UroToday.com) Treatment options for patients with advanced prostate cancer have changed dramatically over the past 10 years. In almost all circumstances, the pivotal phase III trials supporting the use of newer agents have compared active treatment to placebo. This lack of head-to-head trials, along with many guidelines supported treatment approaches has introduced significant uncertainty in this treatment landscape.